132 related articles for article (PubMed ID: 16253811)
1. Biodistribution of 225Ra citrate in mice: retention of daughter radioisotopes in bone.
Kennel SJ; Lankford T; Garland M; Sundberg JP; Mirzadeh S
Nucl Med Biol; 2005 Nov; 32(8):859-67. PubMed ID: 16253811
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors.
Kennel SJ; Chappell LL; Dadachova K; Brechbiel MW; Lankford TK; Davis IA; Stabin M; Mirzadeh S
Cancer Biother Radiopharm; 2000 Jun; 15(3):235-44. PubMed ID: 10941530
[TBL] [Abstract][Full Text] [Related]
3. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.
Henriksen G; Fisher DR; Roeske JC; Bruland ØS; Larsen RH
J Nucl Med; 2003 Feb; 44(2):252-9. PubMed ID: 12571218
[TBL] [Abstract][Full Text] [Related]
4. LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides.
Woodward J; Kennel SJ; Stuckey A; Osborne D; Wall J; Rondinone AJ; Standaert RF; Mirzadeh S
Bioconjug Chem; 2011 Apr; 22(4):766-76. PubMed ID: 21434681
[TBL] [Abstract][Full Text] [Related]
5. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
6. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
Kennel SJ; Brechbiel MW; Milenic DE; Schlom J; Mirzadeh S
Cancer Biother Radiopharm; 2002 Apr; 17(2):219-31. PubMed ID: 12030116
[TBL] [Abstract][Full Text] [Related]
7.
Jiang Z; Revskaya E; Fisher DR; Dadachova E
Curr Radiopharm; 2018; 11(3):215-222. PubMed ID: 29683101
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.
Ma D; McDevitt MR; Finn RD; Scheinberg DA
Appl Radiat Isot; 2001 Nov; 55(5):667-78. PubMed ID: 11573800
[TBL] [Abstract][Full Text] [Related]
9. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
[TBL] [Abstract][Full Text] [Related]
10. Efforts to control the errant products of a targeted in vivo generator.
Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
[TBL] [Abstract][Full Text] [Related]
11. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.
Henriksen G; Breistøl K; Bruland ØS; Fodstad Ø; Larsen RH
Cancer Res; 2002 Jun; 62(11):3120-5. PubMed ID: 12036923
[TBL] [Abstract][Full Text] [Related]
12. LnPO4 nanoparticles doped with Ac-225 and sequestered daughters for targeted alpha therapy.
McLaughlin MF; Robertson D; Pevsner PH; Wall JS; Mirzadeh S; Kennel SJ
Cancer Biother Radiopharm; 2014 Feb; 29(1):34-41. PubMed ID: 24102173
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
Reilly RM; Chen P; Wang J; Scollard D; Cameron R; Vallis KA
J Nucl Med; 2006 Jun; 47(6):1023-31. PubMed ID: 16741313
[TBL] [Abstract][Full Text] [Related]
14. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
15. Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents.
Henriksen G; Bruland OS; Larsen RH
Anticancer Res; 2004; 24(1):101-5. PubMed ID: 15015582
[TBL] [Abstract][Full Text] [Related]
16.
Pfannkuchen N; Bausbacher N; Pektor S; Miederer M; Rosch F
Curr Radiopharm; 2018; 11(3):223-230. PubMed ID: 29866026
[TBL] [Abstract][Full Text] [Related]
17. Cellular dose conversion factors for alpha-particle--emitting radionuclides of interest in radionuclide therapy.
Hamacher KA; Den RB; Den EI; Sgouros G
J Nucl Med; 2001 Aug; 42(8):1216-21. PubMed ID: 11483682
[TBL] [Abstract][Full Text] [Related]
18. Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters.
Hamacher KA; Sgouros G
Med Phys; 2001 Sep; 28(9):1857-74. PubMed ID: 11585217
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
[TBL] [Abstract][Full Text] [Related]
20. Challenges and opportunities in developing Actinium-225 radiopharmaceuticals.
Dhiman D; Vatsa R; Sood A
Nucl Med Commun; 2022 Sep; 43(9):970-977. PubMed ID: 35950353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]